-+ 0.00%
-+ 0.00%
-+ 0.00%

Gelteq publishes MD&A for six months ended Dec. 31, 2025

PUBT·06/30/2026 21:30:40
Listen to the news
Gelteq publishes MD&A for six months ended Dec. 31, 2025
  • Gelteq published its MD&A for the six months ended Dec. 31, 2025, highlighting pipeline expansion across pharmaceutical, animal health, consumer health.
  • Human clinical trial planning completed; trial expected to start next quarter beginning July 1, 2026, supporting a potential FDA pathway.
  • Veterinary clinical trial started for an antiparasitic candidate; FDA application targeted for later in 2026.
  • Preclinical diabetes study launched; development work underway to formulate peptides into stable oral products.
  • Up to USD 3.5 million debt financing signed; commercial product manufactured for a new East Asia customer with delivery expected in July 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gelteq Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073846), on June 30, 2026, and is solely responsible for the information contained therein.